UNSPSC 51181921: Enclomifene

This classification denotes an antiestrogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6D2UI4FLS. European Medicines Agency schedules Enclomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06521MIG. Enclomifene generally arises in the molecular formula C26H28CLNO.

The term ENCLOMIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, no. 10 1975, list 15.) ENCLOMIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enclomifene under HS 29221980 and SITC 51461. SMILES: CL/C(=C(/C1CCC(OCCN(CC)CC)CC1)C1CCCCC1)C1CCCCC1.

UNSPSC 51181921 Enclomifene is a Commodity code covering pharmaceutical products that state and local governments procure through cooperative purchasing frameworks and multi-source contracts. The work being solicited under this code involves manufacturers and distributors supplying generic pharmaceuticals and over-the-counter products to state and local health systems, corrections facilities, and other government agencies. State procurement offices and multistate cooperative purchasing alliances issue RFPs to establish master agreements with pharmaceutical manufacturers that set pricing, guarantee product availability, compliance with manufacturing standards (cGMP and Drug Supply Chain Security Act), and distribution through authorized wholesale channels. Issuing bodies include state departments of administration and multistate cooperative purchasing consortia that bundle procurement across member states and local jurisdictions to achieve volume discounts and standardized supply chains.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (solicitation S1070000015802) to establish multiple contracts for generic pharmaceuticals and OTC products with a March 26, 2026 response deadline. The RFP covers participating state and local government facilities across Minnesota and Oregon, requiring vendors to meet specific manufacturing and regulatory certifications, maintain relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), submit detailed product specifications by National Drug Code, and accept a 3 percent administrative fee on all purchases. Contract awards, effective July 1, 2026, will be weighted 75 percent on price competitiveness, 10 percent on fixed pricing stability, and 5 percent each on administrative compliance, EDI capability, and fee acceptance. Vendors must carry comprehensive insurance including $5 million commercial general liability and comply with FDA requirements and minimum six-month shelf-life standards. The contract term runs two years for new vendors with optional extensions.